UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.155-6, Article 155

2022

Volltextzugriff (PDF)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Cancers, 2021-08, Vol.13 (16), p.4113

2021

Volltextzugriff (PDF)

Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926

PloS one, 2010-12, Vol.5 (12), p.e15262-e15262

2010

Volltextzugriff (PDF)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

Journal of hematology and oncology, 2021-07, Vol.14 (1), p.1-110, Article 110

2021

Volltextzugriff (PDF)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Cancers, 2019-12, Vol.12 (1), p.74

2019

Volltextzugriff (PDF)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Cancers, 2021-10, Vol.13 (21), p.5287

2021

Volltextzugriff (PDF)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

Frontiers in oncology, 2022-01, Vol.11, p.806243-806243

2022

Volltextzugriff (PDF)

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1277-1284

2019

Volltextzugriff (PDF)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2684-2692

2018

Volltextzugriff (PDF)

Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center

Contemporary clinical trials communications, 2024-04, Vol.38, p.101281-101281, Article 101281

2024

Volltextzugriff (PDF)

Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'

Leukemia & lymphoma, 2024, Vol.65 (1), p.141-141

2024

Volltextzugriff (PDF)

The approach of HMA plus VEN with or without BMT for all patients with AML

Hematology, 2023-12, Vol.2023 (1), p.186-191

2023

Volltextzugriff (PDF)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Blood cancer journal (New York), 2021-10, Vol.11 (10), p.175-175, Article 175

2021

Volltextzugriff (PDF)

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Clinical cancer research, 2020-12, Vol.26 (23), p.6132-6140

2020

Volltextzugriff (PDF)

Central nervous system involvement in adult acute myeloid leukemia patients

Leukemia research, 2022-07, Vol.118, p.106882-106882, Article 106882

2022

Volltextzugriff (PDF)

Functional characterization of NPM1-TYK2 fusion oncogene

NPJ precision oncology, 2022-01, Vol.6 (1), p.3-3, Article 3

2022

Volltextzugriff (PDF)

Hedgehog pathway as a drug target: Smoothened inhibitors in development

OncoTargets and therapy, 2012-01, Vol.5 (default), p.47-58

2012

Volltextzugriff (PDF)

Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation

Annals of hematology, 2014-05, Vol.93 (5), p.847-854

2014

Volltextzugriff (PDF)

The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia

Expert review of hematology, 2021-03, Vol.14 (3), p.303-314

2021

Volltextzugriff (PDF)

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

The Lancet. Haematology, 2021-07, Vol.8 (7), p.e481-e491

2021

Volltextzugriff (PDF)

Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

Clinical Medicine Insights. Oncology, 2012-01, Vol.2012 (6), p.205-217

2012

Volltextzugriff (PDF)

Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression

Clinical cancer research, 2020-11, Vol.26 (22), p.5852-5859

2020

Volltextzugriff (PDF)

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

Journal of clinical oncology, 2023-09, Vol.41 (26), p.JCO2202721-4246

2023

Volltextzugriff (PDF)

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells

Leukemia & lymphoma, 2014-02, Vol.55 (2), p.378-391

2014

Volltextzugriff (PDF)

1 – 25 von 466

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(425)
Mit Volltextzugriff
(408)

Publikationsform

Sprache

Englisch
(466)
Japanisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(84)
Journal Of Clinical Oncology
(36)
Biology Of Blood And Marrow Transplantation
(24)
Cell
(21)
Cell Reports
(16)
Cancer Cell
(12)
Nature
(10)
Clinical Lymphoma, Myeloma And Leukemia
(8)
Blood Advances
(7)
Cancer Research
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center

Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'

The approach of HMA plus VEN with or without BMT for all patients with AML

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Central nervous system involvement in adult acute myeloid leukemia patients

Functional characterization of NPM1-TYK2 fusion oncogene

Hedgehog pathway as a drug target: Smoothened inhibitors in development

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation

The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells

Suchergebnisse filtern